trending Market Intelligence /marketintelligence/en/news-insights/trending/8oSVf89zqM0OD9xLcLgdXw2 content esgSubNav
In This List

BriaCell Therapeutics' board approves 1-for-300 reverse stock split

Blog

Global Capital Markets & SPAC Activity – H1 2021

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management


BriaCell Therapeutics' board approves 1-for-300 reverse stock split

BriaCell Therapeutics Corp. said its board approved a consolidation of its shares that was announced in October.

The company will undertake a reverse stock split of its shares at a ratio of 1-for-300, effective Jan. 2, 2020. The West Vancouver, Canada-based company expects to gain a listing on a recognized stock exchange in the U.S. through the reverse split.

BriaCell will reduce its issued and outstanding from 216,589,090 to approximately 721,924 after the split.

BriaCell is a clinical-stage biotechnology company that specializes in immunotherapy for advanced breast cancer. It is currently listed on the TSX-V and the OTCQB.